On Monday 5 October, the Nobel Assembly at Karolinska Institutet announced that Karl Deisseroth, Peter Hegemann and Georg Nagel had won the 2026 Nobel Prize in Physiology or Medicine for optogenetics. Their discoveries made it possible to switch individual nerve cells on and off with light, inside a living brain.
I trained as a psychologist before I moved into marketing, and that sentence gave me goosebumps. One of the first lessons in any psychology degree is that correlation does not prove causation. A brain scan can show which areas become active when someone feels afraid, but it cannot show which cells produce the fear. Optogenetics lets researchers test that directly in laboratory animals: Switch a specific group of cells on or off, and watch what happens to memory, emotion and behaviour. When I finished my MSc in 2004, the method didn’t even exist yet.
There's a lesson for marketers in there too. The switch only worked because the scientists found a precise target, matched it with the right signal, built a way to deliver that signal, and kept going for decades. Changing a buyer's mind depends on the same conditions: Knowing exactly who you're talking to, speaking in terms they respond to, showing up where they already are, and staying consistent over time. Here's what the laureates did, and how to put each lesson to work.
The story begins with Chlamydomonas, a single-celled green alga that swims towards light. Peter Hegemann wanted to know how it manages that, and he’d been studying the question since the mid-1980s. In 2002, working with Georg Nagel and Ernst Bamberg, he identified the gene for a light-sensitive protein the team named channelrhodopsin-1. A year later they described a second one, channelrhodopsin-2: a channel in the cell membrane that opens when blue light hits it, letting positively charged ions rush in. They showed it worked in mammalian cells too, and suggested it could be used to activate other cells with light.
Karl Deisseroth's lab at Stanford took that leap. In 2005, working with Nagel and Bamberg, they put the algal gene into cultured rat nerve cells and showed that flashes of blue light made those neurons fire within milliseconds.
Since then, the switch has reached all the way to memory. In 2013, a team led by Susumu Tonegawa at MIT (a Nobel laureate in 1987) labelled the brain cells holding a mouse's memory of one box. They then placed the mouse in a second box and used light to reactivate that first memory while giving a mild foot shock. Back in the first box, where nothing bad had ever happened, the mice froze in fear. The team had created a false memory.
Neuroscientists had wanted a light switch for brain cells for years. The key ingredient turned up in basic research on pond algae, driven by a question that had nothing to do with the brain: How does a single cell find the light? The Nobel committee traces it all back to Peter Hegemann’s curiosity.
Each of the four ingredients that made optogenetics work translates into something life science marketers can act on this quarter.
Optogenetics works because the gene can be delivered to one specific type of cell while its neighbours are left alone. Back in 1979, Francis Crick had named exactly this as one of neuroscience's great challenges: Controlling one class of neuron while leaving the others more or less unaltered.
Life science marketing can sometimes be guilty of targeting everyone at once - 'stakeholders', 'the market', 'healthcare professionals'. Yet behind every buying decision sits a group of distinct people, each under different pressures. One review identified 33 separate factors shaping physicians' prescribing decisions, from treatment cost and patient preferences to the doctor's own characteristics. A larger review of 146 studies grouped those influences into five levels: Physician, practice, patient, industry and system.
I saw this first-hand during my years as a market researcher, studying how clinicians, patients and payers made decisions for global pharmaceutical companies. The physician was rarely the only person in the decision. Formularies, budget holders and patients all had a hand on the dial, and each needed a different reason to say yes. A single message rarely worked for all of them. So, like the laureates, target one cell type at a time. Map everyone who shapes the decision, then write separately for the hospital pharmacist, the procurement lead and the principal investigator, based on what each person really cares about.
Channelrhodopsin-2 responds to blue light. When researchers took optogenetics into a human eye for the first time, they used a different version, ChrimsonR, which is tuned towards amber light, and built special goggles to deliver it. In 2021 they reported that a 58-year-old man diagnosed with retinitis pigmentosa 40 years earlier and able to perceive only light, could now perceive, locate and count objects with the treated eye while wearing the goggles. It was the first reported partial recovery of function in a neurodegenerative disease after optogenetic therapy.
The lesson for marketers: The signal has to match the receiver. KOLs are tuned to data and peer credibility. Payers respond to budget impact and risk. Investors look for milestones and the strength of the team. Patients want to know what changes in their daily life. Send the right message at the wrong wavelength and it simply won't register.
Even the perfect protein does nothing if the light can't reach it. In animal studies, that has often meant fibre optics carrying light deep into the brain. In the vision trial, the patient could see nothing with the treated eye when he took the goggles off, and training with them only began nearly five months after the injection, once the protein had time to settle into the cells.
Your positioning is the signal you want your audience to receive. Content is how that signal travels, and your channels are the fibre optics that carry it to the right place. A brilliant positioning statement that lives only in a brand book never reaches anyone. It starts to work when every article, post and webinar expresses it, consistently, in the places your audience already spends its time, for long enough to take effect.
Optogenetics took almost 50 years to go from idea to Nobel Prize:
Thankfully, life science buying cycles aren't THAT long (phew). But they’re still pretty long. Trust in a new diagnostic, a CDMO or a platform technology builds over years of credible, useful content. A one-off launch campaign is a single flash of light.
Nobel week puts science on front pages around the world. You can make the most of that attention without casting a shadow on anyone else's spotlight:
Explain the science. If your work genuinely connects to this year’s prize (neuroscience research tools, gene delivery, light-based technologies, retinal disease), publish a clear, plain-language explainer of the science and where your work fits. It gives your sales team something useful to share long after Nobel week.
Tell your own pond algae story. Many companies have an unglamorous, weird, unexpected beginning. This week, audiences are primed to love it. Share yours with the world.
Celebrate the basic research behind your product. Many therapies stand on decades of curiosity-driven science. Naming the researchers and discoveries you build on shows humility and earns credibility with scientific audiences.
My first career was as a psychologist in the prison and probation service, delivering cognitive-behavioural programmes designed to change how people thought and acted. Nobody walked out of a single session transformed. When change came, it came slowly - through the relationship in the room, through practising new ways of thinking again and again, and through what was waiting for those people when they left.
That experience is why the 2026 prize really struck a chord with me. People change their minds much the way those neurons fire: When the right signal reaches the right target, reliably, over time. The good news for marketers is that every one of those conditions is within our control.
This year's laureates gave neuroscience a tool that laboratories around the world now use to explore memory, emotion and behaviour. It began with someone wondering how a speck of algae finds the light.
A little of that curiosity and patience goes a long way in life science marketing. Get to know exactly who you need to reach, speak in terms they respond to, show up where they already spend their time, and keep going long after launch.
This is the work we do every day at UP FOR LIFE, for global life science leaders and ambitious scale-ups. We start with research and workshops to pinpoint who really makes the decision. We build brand strategy and messaging that speaks their language. Then we create the content, campaigns and digital channels that keep your message in front of them, month after month. And it really works. For Tecan, that approach grew organic website traffic by 300%.
Key sources